Hyperthermia · Pathogen Targeting · Treatment
Heat has been used medicinally for thousands of years — from the therapeutic baths of ancient Rome to the fever chambers of early modern medicine. The underlying biological principle has always been sound: many pathogens are significantly more vulnerable to elevated temperature than human tissue is. The challenge has always been achieving and sustaining therapeutic temperatures safely.
Systemic Perfusion Hyperthermia — SPH — solves that challenge with a precision that was not possible until relatively recently. Under continuous hospital monitoring, core body temperature is raised to therapeutic levels using an external perfusion circuit, held there for a controlled period, then carefully reduced. The result is a whole-body thermal environment that Lyme pathogens cannot tolerate — while the patient's vital systems remain continuously supported and monitored.
Human cells evolved with a highly regulated thermal range. The processes that govern protein folding, enzyme function, and cellular repair are calibrated for a core temperature between 36.5°C and 37.5°C — and have a meaningful but limited tolerance for elevation above that range.
Borrelia burgdorferi, by contrast, is a spirochete that originated in tick vectors — organisms that experience wide temperature variation and whose internal environments are far less thermally stable than the mammalian body. Research has shown that Borrelia's structural proteins, membrane components, and enzymatic processes are substantially more sensitive to elevated temperature than human cellular systems.
At the therapeutic temperatures achieved through SPH, Borrelia experiences thermal stress that disrupts its protein architecture, impairs its motility, compromises its outer membrane integrity, and inhibits its replication machinery. Human cells, maintained under continuous physiological support, tolerate these temperatures within a defined therapeutic window.
The key principle: SPH does not harm human tissue to harm the pathogen. It exploits the differential thermal tolerance between human cells and Borrelia — pushing temperature into a range the bacterium cannot sustain while the patient's vital systems are continuously monitored and supported.
Systemic Perfusion Hyperthermia targets several of the biological mechanisms that make chronic Lyme disease so difficult to treat with conventional approaches alone.
SPH is a hospital-based procedure performed under continuous medical monitoring by our clinical team. It is not a sauna, an infrared device, or a localized heat application. It is a systemic intervention that requires full physiological support throughout.
The patient is sedated and connected to an external perfusion circuit that heats the blood as it passes through, gradually raising core body temperature to the therapeutic target. Throughout the procedure, vital signs — temperature, cardiac function, oxygen saturation, blood pressure, and metabolic parameters — are monitored continuously. Cooling protocols are prepared and immediately available.
The therapeutic temperature is maintained for a defined period calibrated to the patient's physiology and treatment protocol, then carefully reduced through a controlled cooling phase. Patients recover in a monitored setting before discharge or transfer to the outpatient facility.
SPH is a significant medical procedure, and appropriate patient selection is essential. Not every chronic Lyme patient is a candidate, and the clinical evaluation prior to treatment is thorough.
Patients with significant cardiac conditions, uncontrolled hypertension, severe anemia, or certain other medical comorbidities may not be suitable candidates. The pre-treatment evaluation includes laboratory work, cardiac assessment, and a thorough review of medical history to confirm eligibility before any treatment is scheduled.
Systemic Perfusion Hyperthermia is most effective when it is not used in isolation. At the Lyme Immunotherapy Center, SPH is typically combined with Therapeutic Apheresis — a blood filtration procedure that removes the inflammatory debris, cytokines, and immune complexes that hyperthermia releases into circulation. This sequencing is deliberate: apheresis clears the toxic burden that SPH mobilizes, creating a cleaner internal environment for subsequent immune interventions.
In our comprehensive 18-day protocol, SPH follows apheresis and precedes Treg therapy — the sequence designed to create the optimal conditions for each intervention to work at maximum efficacy. Reducing pathogen burden and clearing inflammatory debris before reintroducing regulatory immune cells gives those cells a significantly better environment to establish themselves in.
Our clinical team evaluates each patient individually to determine whether SPH is appropriate and how it fits within your broader treatment protocol.
Check My Eligibility